Why Fragmented Patent Ownership Triggers the 'Tragedy of the Anticommons'

The classic "tragedy of the commons" describes a shared pasture overgrazed to ruin because no single farmer has the right to exclude others. The "tragedy of the anticommons" operates as its exact mirror image: a resource is entirely wasted through underuse because too many owners possess the right to exclude each other, and no single party can secure the privilege of use. Michael Heller first formalized this concept after observing the empty storefronts of post-Soviet Moscow in the 1990s. While street kiosks flourished in the bitter cold, prime retail spaces remained vacant because too many bureaucratic entities held overlapping veto rights over their use. No one could open a shop without paying off half a dozen agencies, so the resource simply sat idle.[2]

In 1998, legal scholars Michael Heller and Rebecca Eisenberg introduced this framework in the journal Science to describe a looming crisis in biomedical research. As they wrote, "A resource is prone to underuse in a 'tragedy of the anticommons' when multiple owners each have a right to exclude others from a scarce resource and no one has an effective privilege of use." They argued that the proliferation of intellectual property rights in upstream research—such as gene fragments and receptors—was creating a gridlock that would block downstream drug discovery. If a pharmaceutical company needed fifty separate licenses just to begin testing a compound, the transaction costs would theoretically paralyze the development pipeline.[1]

This phenomenon, often termed a "patent thicket," describes a dense web of overlapping intellectual property rights that a company must hack its way through to commercialize new technology. The logic is intuitively terrifying for complex technologies. A modern smartphone or a next-generation biologic drug does not rely on a single invention; it is an assembly of thousands of distinct, patented components. The Boston University School of Law scholarship on strategic patenting highlights how firms deliberately construct these thickets. By patenting every conceivable variation of a technology, companies create defensive perimeters that force competitors to the negotiating table. The sheer volume of claims turns the patent system from a mechanism of disclosure into a minefield of litigation risk.[3]

Yet, nearly three decades after Heller and Eisenberg’s warning, the empirical evidence presents a starkly different reality. The argument that patent fragmentation universally suppresses commercialization is fundamentally flawed. While the anticommons effect is a real localized failure condition, it is not the universal law of innovation its proponents feared. The Factlen Editorial Team's synthesis of the literature reveals that markets are highly adaptive to transaction costs. When the financial incentives are sufficiently large, the theoretical gridlock of the anticommons is routinely dismantled by practical business imperatives.[8]

The Council for Innovation Promotion (C4IP), analyzing patent data in 2025, concluded that "the data doesn't support the existence of so-called patent 'thickets'." Instead of gridlock, heavily patented industries like telecommunications and semiconductors have demonstrated rapid, sustained innovation. C4IP argues that the narrative of the anticommons relies too heavily on theoretical models rather than real-world commercial outcomes. When thousands of patents cover a single 5G standard, the result is not a halt in smartphone production. Instead, the industry relies on standard-essential patents and fair, reasonable, and non-discriminatory (FRAND) licensing commitments to ensure that the technology is widely adopted while inventors are compensated.[5]

The University of Akron School of Law’s Intellectual Property and Policy Initiative echoed this sentiment in late 2025, pointing out the core problem with the thicket narrative. Firms bypass the anticommons through private ordering mechanisms: cross-licensing agreements, patent pools, and joint ventures. When two tech giants realize they are mutually blocked by each other's patent portfolios, they rarely cease production. Instead, they sign broad cross-licensing deals that grant mutual freedom to operate. This private ordering effectively recreates the commons for the major players involved. While it may raise the barrier to entry for new startups who lack a portfolio to trade, it does not result in the absolute underuse of the resource that Heller and Eisenberg originally predicted.

A 2014 working paper from the Organisation for Economic Co-operation and Development (OECD) on patent thickets highlights this dynamic at a macroeconomic level. The OECD noted that while the sheer volume of patents has increased dramatically, firms have adapted by forming complex, interconnected licensing networks. The transaction costs of navigating these networks certainly exist, but they function as a tax on innovation rather than an absolute barrier. The OECD data suggests that while thickets may reduce the efficiency of the market, they rarely cause the catastrophic market failure associated with a true tragedy of the anticommons. The critical variable is not the number of patents, but the willingness of the patent holders to negotiate. As long as the rights are held by commercial entities motivated by profit, a clearing price can usually be found.[4]

So where does the anticommons actually manifest? The failure condition triggers specifically when downstream product development requires assembling fragmented rights from disparate institutional cultures—particularly public-private partnerships—rather than purely private cross-licensing. When a commercial firm attempts to license technology from a university technology transfer office, a government laboratory, and a rival corporation simultaneously, the standard mechanisms of private ordering break down. A university may prioritize academic publication and broad access, while a private firm demands strict exclusivity to justify its venture capital funding. Bridging that gap requires bespoke, high-friction negotiations.[8]

A 2025 study published in Taylor & Francis on the genetic data market illustrates this exact friction. When academic institutions, government labs, and private pharmaceutical companies attempt to collaborate on genomic research, their divergent goals make negotiating licenses exponentially more difficult. The study found that institutional governance of these research partnerships often struggles to balance the public good with commercial incentives. In these specific intersections, the transaction costs of aligning different institutional values can indeed stall the development of new therapies, mirroring the exact gridlock Heller and Eisenberg warned about. The data market becomes fragmented not just by legal rights, but by ethical and bureaucratic mandates that cannot be easily resolved with a simple royalty payment.[6]

The University of Michigan Law School’s scholarship on proprietary research tools further clarifies this boundary. The anticommons is avoided when the costs of negotiation are low and the norms of the industry support sharing. But when institutional inertia takes hold, and universities overvalue their upstream patents in hopes of securing a blockbuster royalty, the system freezes. The research tools necessary for basic scientific discovery become locked behind prohibitive licensing terms, effectively taxing the foundational steps of the scientific method itself. In these cases, the patent system fails its constitutional mandate to promote the progress of science, instead acting as a tollbooth on the road to discovery.[7]

The biomedical patent landscape only resembles those empty Moscow storefronts when the owners refuse to negotiate on commercial terms. The tragedy of the anticommons is not a structural inevitability of having too many patents. It is a behavioral failure that occurs when patent holders prioritize the theoretical value of exclusion over the practical value of commercialization. Whether through compulsory licensing for essential research tools, the establishment of public patent pools for genetic data, or simply reforming university technology transfer mandates, the goal must be to lower the transaction costs of collaboration. The pasture only dies when the gates are locked and the keys are lost.[2][8]